Holen Sie sich die Stockscreener-App
12.27
2.25%
0.27
Schlusskurs vom Vortag:
$12.00
Offen:
$11.87
24-Stunden-Volumen:
249.08K
Relative Volume:
0.32
Marktkapitalisierung:
$445.30M
Einnahmen:
$10.00M
Nettoeinkommen (Verlust:
$-75.99M
KGV:
-5.1397
EPS:
-2.3873
Netto-Cashflow:
$-80.36M
1W Leistung:
-7.26%
1M Leistung:
-6.41%
6M Leistung:
-47.99%
1J Leistung:
+0.00%
1-Tages-Spanne:
$11.87
$12.46
1-Wochen-Bereich:
$11.70
$13.13
52-Wochen-Spanne:
$10.47
$33.20
Evommune Inc Stock (EVMN) Company Profile
Firmenname
Evommune Inc
Sektor
Branche
Telefon
(650) 223-7745
Adresse
1891 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
12.27 | 492.48M | 10.00M | -75.99M | -80.36M | -2.3873 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-07 | Fortgesetzt | Oppenheimer | Outperform |
| 2026-01-22 | Eingeleitet | Oppenheimer | Outperform |
| 2026-01-08 | Eingeleitet | Raymond James | Strong Buy |
| 2026-01-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-12-01 | Eingeleitet | Evercore ISI | Outperform |
| 2025-12-01 | Eingeleitet | Leerink Partners | Outperform |
| 2025-12-01 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-01 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Evommune Inc Aktie (EVMN) Neueste Nachrichten
Evommune (EVMN) Financial Update: EPS Misses Its Estimate in Latest Trading; Trading Move: Shares Move 10.63% Down in Latest TradingProfit Margin Analysis - vinanet.vn
Evommune (NYSE:EVMN) Trading Down 6.9%Here's What Happened - MarketBeat
Evommune Inc (EVMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evommune Inc. (EVMN) Rises 4.12% to $14.65 as Clinical-Stage Biotech Draws Fresh InterestHull Moving Average - vinanet.vn
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
Evommune (EVMN) Slips 0.42% to $14.06 as Consolidation Tightens Around Key SupportBreakout Stock Alerts - Vinanet
HC Wainwright Issues Negative Estimate for Evommune Earnings - MarketBeat
Evommune Inc. (EVMN) Holds Steady at $14.07 as Consolidation ContinuesDebt Free Companies - vinanet.vn
Analysts Conflicted on These NA Names: Bob’s Discount Furniture, Inc. (BOBS), Evommune, Inc. (EVMN) and Once Upon a Farm, PBC (OFRM) - The Globe and Mail
Evommune, Inc. (NYSE:EVMN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Evommune (NYSE:EVMN) Price Target Cut to $29.00 by Analysts at Royal Bank Of Canada - MarketBeat
Evommune, Inc. Stock 12‑Month Price Target Cut to $30.11, Implies 125% Upside - TradingView
Evommune Inc (EVMN) Stock News Today - TradingKey
RBC Adjusts PT on Evommune to $29 From $30, Maintains Outperform Speculative Risk Rating - marketscreener.com
Evommune Inc (EVMN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
EVMN: Advancing two novel anti-inflammatory therapies with strong clinical and financial momentum - TradingView
EVMN: Strong cash reserves support key clinical milestones despite higher losses and no Q2 revenue - TradingView
Evommune reports Q2 2026 net loss of $32.2M, cash $288.0M; EVO756 Phase 2b AD readout due Sept 2026 - TradingView
Evommune, Inc. 2Q 2026: Revenue $0 Net loss $53.9M — 10-Q Summary - TradingView
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Business Wire
Migraine Biotech Doses First Patient in Phase 2b EVO756 Trial - Streetwise Reports
Evommune Inc. (EVMN) Advances 2.76% as Shares Test Key Resistance Near $14Aggressive Growth Picks - vinanet.vn
Evommune Inc. (EVMN) Holds Near $13.09 as Biotech Stock Consolidates Between Key LevelsUndervalued Stocks - dars.gov.et
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), LB Pharmaceuticals, Inc. (LBRX) and SpaceX (SPCX) - The Globe and Mail
896,700 Shares in Evommune, Inc. $EVMN Purchased by Janus Henderson Group PLC - MarketBeat
HC Wainwright Reiterates Neutral Rating for Evommune (NYSE:EVMN) - MarketBeat
Evommune stock: H.C. Wainwright reiterates Neutral rating By Investing.com - Investing.com India
Evommune stock: H.C. Wainwright reiterates Neutral rating - Investing.com
EVMN Q1 2026 Earnings: Narrower Loss Beats Estimates by 15.6% Amid No RevenuePre-Earnings Drift - vinanet.vn
Evommune doses first patient in migraine prevention trial By Investing.com - Investing.com Nigeria
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis - Yahoo Finance
EVMN Q1 2026 Earnings: EPS Surprises to the Upside as Clinical Pipeline AdvancesRevenue Beat Analysis - vinanet.vn
Evommune Inc (EVMN) Institutional Confidence - TradingKey
Evommune Inc (EVMN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Evommune Inc (EVMN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Evommune, Inc. $EVMN Stake Lessened by Octagon Capital Advisors LP - MarketBeat
Evommune Inc (EVMN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
EVMN|Evommune Inc|Price:11.480|Chg%:+0.120 - TradingKey
EVMN|Evommune Inc|Price:11.600|Chg%:+0.350 - TradingKey
Evommune Inc (EVMN) Cash Flow - TradingKey
Evommune Inc (EVMN) Income Statement - TradingKey
Evommune, Inc. Revenue Breakdown – NYSE:EVMN - TradingView
EVMN|Evommune Inc|Price:13.490|Chg%:+0.470 - TradingKey
Evommune Inc (EVMN) Balance Sheet - TradingKey
Evommune Inc (EVMN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Evommune Inc (EVMN) Valuation: PE, PB & Fair Value Analysis - TradingKey
EVMN|Evommune Inc|Price:11.360|Chg%:+0.060 - TradingKey
Evommune Inc. (EVMN) Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineFinancial Health Score - po-news-eg.net
Evommune (EVMN) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Call Transcript - vinanet.vn
Evommune Inc. (EVMN) Q1 2026 Earnings: EPS Surprise Exceeds Expectations Amid Pre-Revenue StageBanking Earnings Report - dars.gov.et
Evommune Inc. (EVMN) Q1 2026 Earnings: Narrower Loss Highlights Cost Discipline for Pre-Revenue BiotechBalance Sheet Strength - vinanet.vn
Finanzdaten der Evommune Inc-Aktie (EVMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Evommune Inc-Aktie (EVMN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KIRSCH ARTHUR S | Director |
Jul 07 '26 |
Buy |
13.30 |
10,000 |
133,000 |
10,000 |
| Drew Janice Suzann | Chief of Dev. Operations |
Jun 22 '26 |
Option Exercise |
3.15 |
20,000 |
63,063 |
87,794 |
| Drew Janice Suzann | Chief of Dev. Operations |
Jun 22 '26 |
Sale |
22.63 |
20,000 |
452,600 |
67,794 |
| Patel Jeegar Pravinkumar | Chief Scientific Officer |
Jun 22 '26 |
Option Exercise |
3.84 |
1,488 |
5,714 |
47,891 |
| Patel Jeegar Pravinkumar | Chief Scientific Officer |
Jun 22 '26 |
Sale |
22.50 |
1,488 |
33,480 |
46,403 |
| Pena Luis C. | President & CEO |
Jun 22 '26 |
Sale |
22.71 |
7,438 |
168,917 |
630,458 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):